World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
108
Citations
49509
World Ranking
5943
National Ranking
3179

Robert L. Coleman publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Robert L. Coleman sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 835 publications — 89th percentile

89% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Robert L. Coleman D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Robert L. Coleman sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 108 D-Index — 71st percentile

71% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Robert L. Coleman is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily focuses on medicine, with significant contributions in reproductive medicine, oncology, obstetrics and gynecology, pulmonary and respiratory medicine, and molecular biology. The scientist's work encompasses a range of topics related to cancer diagnosis and treatment, including ovarian cancer diagnosis and treatment, PARP inhibition in cancer therapy, endometrial and cervical cancer treatments, cancer genomics and diagnostics, BRCA gene mutations in cancer, lung cancer treatments and mutations, and toxin mechanisms and immunotoxins.

Selected recent papers authored by Robert L. Coleman include:

  • Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study, 2021, The Lancet Oncology

Frequent coauthors collaborating with Coleman are:

  • Bradley J. Monk
  • David M. O'Malley
  • Kathleen N. Moore
  • Brian M. Slomovitz
  • Shannon N. Westin

The scientist frequently publishes in the following venues:

  • Gynecologic Oncology
  • Journal of Clinical Oncology
  • International Journal of Gynecological Cancer
  • Annals of Oncology
  • Cancer Research

The scope of Coleman's work addresses critical aspects of oncology and gynecologic cancer treatment, contributing to multidisciplinary fields with over 700 publications in medicine-related topics. Their research integrates clinical and translational approaches within reproductive medicine and oncology, with a particularly strong focus on ovarian, endometrial, and cervical cancer therapies. This is reflected in the range of journals and coauthors associated with the scientist.

Best Publications

  • Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer

    Pedro Tomas Ramirez;Michael Frumovitz;Rene Pareja;Aldo Lopez

  • Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

    Robert L Coleman;Amit M Oza;Domenica Lorusso;Carol Aghajanian

  • Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma

    Premal H Thaker;Liz Y Han;Aparna A Kamat;Jesusa M Arevalo

  • Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial

    Elizabeth M Swisher;Kevin K Lin;Amit M Oza;Clare L Scott

  • RNA interference in the clinic: challenges and future directions

    Chad V. Pecot;George A. Calin;Robert L. Coleman;Gabriel Lopez-Berestein

  • Dicer, Drosha, and outcomes in patients with ovarian cancer

    William M. Merritt;Yvonne G. Lin;Liz Y. Han;Aparna A. Kamat

  • Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline ☆

    Alexi A. Wright;Kari Bohlke;Deborah K. Armstrong;Michael A. Bookman

  • Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook.

    Josep Garcia;Herbert I. Hurwitz;Alan B. Sandler;David Miles

  • Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer

    Robert L. Coleman;Gini F. Fleming;Mark F. Brady;Elizabeth M. Swisher

  • Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial

    Robert L. Coleman;Mark F. Brady;Thomas J. Herzog;Paul Sabbatini

  • Latest research and treatment of advanced-stage epithelial ovarian cancer

    Robert L. Coleman;Bradley J. Monk;Anil K. Sood;Thomas J. Herzog

  • Preclinical and clinical development of siRNA-based therapeutics

    Gulnihal Ozcan;Bulent Ozpolat;Robert L. Coleman;Anil K. Sood

  • Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer

    Charles N. Landen;Blake Goodman;Ashwini A. Katre;Adam D. Steg;Adam D. Steg

  • The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer

    Brian M. Slomovitz;Robert L. Coleman

  • Regulation of Tumor Angiogenesis by EZH2

    Chunhua Lu;Hee Dong Han;Lingegowda S. Mangala;Rouba Ali-Fehmi

  • Exploring and comparing adverse events between PARP inhibitors.

    Christopher J LaFargue;Graziela Z Dal Molin;Anil K Sood;Robert L Coleman

  • Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study

    John Farley;William E Brady;Vinod Vathipadiekal;Heather A Lankes

  • Lymphatic Mapping and Sentinel Lymph Node Biopsy in Women With Squamous Cell Carcinoma of the Vulva: A Gynecologic Oncology Group Study

    Charles F. Levenback;Shamshad Ali;Robert L. Coleman;Michael A. Gold

  • Focal Adhesion Kinase Targeting Using In vivo Short Interfering RNA Delivery in Neutral Liposomes for Ovarian Carcinoma Therapy

    Jyotsnabaran Halder;Aparna A. Kamat;Charles N. Landen;Liz Y. Han

  • Lymphatic Mapping and Sentinel Node Identification in Patients With Cervix Cancer Undergoing Radical Hysterectomy and Pelvic Lymphadenectomy

    Charles Levenback;Robert L. Coleman;Thomas W. Burke;W. Michael Lin

Frequent Co-Authors

Anil K. Sood
Anil K. Sood The University of Texas MD Anderson Cancer Center
Bradley J. Monk
Bradley J. Monk University of Arizona
Thomas J. Herzog
Thomas J. Herzog University of Cincinnati
David M. O'Malley
David M. O'Malley The Ohio State University
David M. Gershenson
David M. Gershenson The University of Texas MD Anderson Cancer Center
Amit M. Oza
Amit M. Oza Princess Margaret Cancer Centre
Elizabeth M. Swisher
Elizabeth M. Swisher University of Washington
Ana Oaknin
Ana Oaknin Vall d'Hebron Hospital Universitari
Carol Aghajanian
Carol Aghajanian Memorial Sloan Kettering Cancer Center
Pedro Tomas Ramirez
Pedro Tomas Ramirez The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering studying Medicine in the USA, you may also be interested in related online degrees and flexible career pathways within healthcare. The demand for skilled professionals is growing, and online programs can make advanced education more accessible and affordable.

For nursing professionals looking to advance, an online PhD in nursing offers opportunities for research, leadership, and teaching at the highest levels. Those who are already registered nurses but want to complete their bachelor’s degree can explore cheap rn to bsn programs for an affordable, flexible option.

If you have a non-nursing bachelor’s degree but want to transition into nursing, direct entry msn programs can help you fast-track your education and enter the field efficiently. For those interested in accessible training and admissions, it’s worth researching what is the easiest nursing school to get into to find a program that matches your needs and background.

Exploring these online pathways can open doors to rewarding healthcare careers beyond traditional medical school routes.

Best Scientists Citing Robert L. Coleman

Trending Scientists

Recently Published Articles